Smooth muscle invasion selects for aggressive prostate cancer

平滑肌侵袭选择侵袭性前列腺癌

基本信息

  • 批准号:
    10642703
  • 负责人:
  • 金额:
    $ 5.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT The most common non-cutaneous cancer in American men, prostate cancer is characterized by a substantial degree of overdiagnosis and is consequently a significant source of morbidity and driver of unnecessary cost. There is therefore a significant need to identify prostate cancer patients who need aggressive therapy compared to those who need no treatment at all. The cancer-specific mortality of these tumors is attributable to metastatic disease. Adenocarcinoma of the prostate must interact with smooth muscle at multiple steps of the metastatic process, including intravasation and extravasation between the bloodstream and tissue. In addition, the cancer- prone peripheral zone of the human prostate gland is composed of a fibromuscular stroma and bounded by a smooth muscle capsule. While the current paradigm for most cancers is that local invasion is not predictive of aggressive disease, this is not the case with prostate cancer. Aggressive prostate cancer cells are directly observed as extending past the smooth muscle capsule in clusters, in a process called extracapsular extension (ECE), thereby escaping organ confinement. The presence of ECE defines the pT3a category in the pathologic staging of prostatic adenocarcinoma and is associated with an increased risk of biochemical recurrence, distant metastases and cancer-specific mortality. Although smooth muscle invasion is required for ECE, intravasation, and extravasation to distant sites, there are no markers of the switch from indolent to aggressive, muscle-invasive prostate cancer. This work is therefore concentrated on understanding the molecular events that regulate ECE to prevent this critical step in the metastatic process. The central hypothesis is that invasion through the smooth muscle capsule requires unique molecular properties that predict aggressive cancer. If correct, the concept will change current standard of care by providing new molecular discriminators of indolent versus aggressive disease. Objective measures of the aggressive disease transition will inform treatment decisions and help to direct the appropriate level of treatment for the degree of disease aggression.
项目概要/摘要 前列腺癌是美国男性中最常见的非皮肤癌,其特点是大量 过度诊断的程度,因此是发病率的重要来源和不必要费用的驱动因素。 因此,非常需要确定与癌症相比需要积极治疗的前列腺癌患者。 对于那些根本不需要治疗的人。这些肿瘤的癌症特异性死亡率可归因于转移性 疾病。前列腺腺癌必须在转移的多个步骤中与平滑肌相互作用 过程,包括血流和组织之间的内渗和外渗。此外,癌症—— 人类前列腺的外周区由纤维肌性基质组成,并以 平滑肌囊。虽然大多数癌症的当前范例是局部侵袭并不能预测 侵袭性疾病,但前列腺癌则不是这种情况。攻击性前列腺癌细胞直接 观察到成簇延伸穿过平滑肌囊,这一过程称为囊外延伸 (ECE),从而逃脱器官限制。 ECE 的存在定义了病理学中的 pT3a 类别 前列腺腺癌的分期与生化复发、远处转移的风险增加相关 转移和癌症特异性死亡率。虽然ECE需要平滑肌浸润,但内渗、 和外渗到远处部位,没有从惰性转变为攻击性、肌肉侵入性的标志 前列腺癌。因此,这项工作的重点是了解调节 ECE 的分子事件 以防止转移过程中的这一关键步骤。中心假设是,入侵是通过 平滑肌囊需要独特的分子特性来预测侵袭性癌症。如果正确的话, 这一概念将通过提供新的惰性与惰性分子鉴别器来改变当前的护理标准。 侵袭性疾病。侵袭性疾病转变的客观测量将为治疗决策提供信息 有助于根据疾病侵袭程度指导适当的治疗水平。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Integrins and Epithelial-Mesenchymal Cooperation in the Tumor Microenvironment of Muscle-Invasive Lethal Cancers.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kendra Danice Marr其他文献

Kendra Danice Marr的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kendra Danice Marr', 18)}}的其他基金

Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10207448
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:
Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10405525
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:
Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10065891
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:

相似海外基金

Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
TAZ 和 YAP 在 3D 基因组组织 DNA 损伤修复中的新作用以及胶质母细胞瘤的治疗耐药性
  • 批准号:
    10649830
  • 财政年份:
    2023
  • 资助金额:
    $ 5.21万
  • 项目类别:
Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10207448
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:
Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10405525
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:
Smooth muscle invasion selects for aggressive prostate cancer
平滑肌侵袭选择侵袭性前列腺癌
  • 批准号:
    10065891
  • 财政年份:
    2020
  • 资助金额:
    $ 5.21万
  • 项目类别:
Project 2 - Mechanisms linking Cancer Disparities and Metabolic Status
项目 2 - 连接癌症差异和代谢状态的机制
  • 批准号:
    10204739
  • 财政年份:
    2017
  • 资助金额:
    $ 5.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了